Biblio

Author Title [ Type

] Year

Filters: Author is Stelljes, Matthias [Clear All Filters]

Journal Article

Spyridonidis A, Labopin M, Gedde-Dahl T, Ganser A, Stelljes M, Craddock C, Wagner-Drouet EMaria, Versluis J, Schroeder T, Blau IWolfgang, et al. Validation of the transplant conditioning intensity (TCI) index for allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2023.

Ruggeri A, Battipaglia G, Labopin M, Ehninger G, Beelen D, Tischer J, Ganser A, Schwerdtfeger R, Glass B, Finke J, et al. Unrelated donor versus matched sibling donor in adults with acute myeloid leukemia in first relapse: an ALWP-EBMT study. J Hematol Oncol. 2016;9(1):89.

Beelen DWilhelm, Trenschel R, Stelljes M, Groth C, Masszi T, Reményi P, Wagner-Drouet E-M, Hauptrock B, Dreger P, Luft T, et al. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 . Lancet Haematol. 2019.

Hirschbühl K, Labopin M, Polge E, Blaise D, Bourhis JHenri, Socié G, Forcade E, Yakoub-Agha I, Labussière-Wallet H, Bethge W, et al. Total body irradiation versus busulfan based intermediate intensity conditioning for stem cell transplantation in ALL patients >45 years-a registry-based study by the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplant. 2023.

Kharfan-Dabaja MA, Labopin M, Brissot E, Kröger N, Finke J, Ciceri F, Deconinck E, Blaise D, Chevallier P, Gramatzki M, et al. Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated versus T-cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia. Br J Haematol. 2021.

Nagler A, Labopin M, Kröger N, Schroeder T, Gedde-Dahl T, Eder M, Franke G-N, Blau IWolfgang, Salmenniemi U, Socié G, et al. The role of anti-thymocyte globulin in allogeneic stem cell transplantation (HSCT) from HLA-matched unrelated donors (MUD) for secondary AML in remission: a study from the ALWP /EBMT. Bone Marrow Transplant. 2023.

Friedrichs B, Stelljes M, Schmitz N. The role of allogeneic stem cell transplantation in T-cell lymphoma. Curr Opin Oncol. 2018;30(5):301-307.

Stelljes M, Middeke JMoritz, Bug G, Wagner-Drouet E-M, Müller LP, Schmid C, Krause SW, Bethge W, Jost E, Platzbecker U, et al. Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial. Lancet Haematol. 2024.

Niederwieser C, Iacobelli S, Franke G-N, Koster L, van Os M, Platzbecker U, Hübel K, Scheid C, Müller LPeter, Stelljes M, et al. Reduced intensity versus myeloablative conditioning for MDS: long-term results of an EBMT phase III study (RICMAC). Bone Marrow Transplant. 2024.

Ayuk FAyuketang, Gagelmann N, von Tresckow B, Wulf GGeorg, Rejeski K, Stelljes M, Penack O, Baldus CD, Kröger N, Bethge WAndreas, et al. Real-world results of CAR-T cell therapy for large B-cell lymphoma with CNS involvement: a GLA/DRST study. Blood Adv. 2023.

Gerbitz A, Gary R, Aigner M, Moosmann A, Kremer A, Schmid C, Hirschbuehl K, Wagner E, Hauptrock B, Teschner D, et al. Prevention of CMV/EBV reactivation by double-specific T cells in patients after allogeneic stem cell transplantation: results from the randomized phase I/IIa MULTIVIR-01 study. Front Immunol. 2023;14:1251593.

Pohlmann A, Bentgens E, Schülke C, Kuron D, Reicherts C, Marx J, Angenendt L, Mikesch J-H, Lenz G, Stelljes M, et al. Pretransplant spleen volume and outcome after hematopoietic stem cell transplantation (HSCT) in patients with acute myeloid leukemia (AML). Ann Hematol. 2023.

Nagler A, Labopin M, Swoboda R, Schroeder T, Hamladji R-M, Griškevičius L, Salmenniemi U, Rambaldi A, Mielke S, Kulagin A, et al. Post-transplant cyclophosphamide, calcineurin inhibitor, and mycophenolate mofetil compared to anti-thymocyte globulin, calcineurin inhibitor, and methotrexate combinations as graft-versus-host disease prophylaxis post allogeneic stem cell transplantation. Bone Marrow Transplant. 2024.

Groth C, van Groningen LFJ, Matos TR, Bremmers ME, Preijers FWMB, Dolstra H, Reicherts C, Schaap NPM, van Hooren EHG, IntHout J, et al. Phase I/II trial of a combination of anti-CD3/CD7 immunotoxins for steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant. 2018.

Schliemann C, Kessler T, Berdel AF, Hemmerle T, Angenendt L, Altvater B, Rossig C, Mikesch J-H, Lenz G, Schäfers M, et al. Phase I study of F16IL2 antibody-cytokine fusion with very low-dose araC in acute myeloid leukaemia relapse after allogeneic stem cell transplantation. Br J Haematol. 2021.

Pohlen M, Thoennissen NH, Braess J, Thudium J, Schmid C, Kochanek M, Kreuzer K-A, Lebiedz P, Görlich D, Gerth HU, et al. Patients with Acute Myeloid Leukemia Admitted to Intensive Care Units: Outcome Analysis and Risk Prediction. PLoS One. 2016;11(8):e0160871.

Marks DI, Kebriaei P, Stelljes M, Gökbuget N, Kantarjian H, Advani AS, Merchant A, Stock W, Cassaday RD, Wang T, et al. Outcomes of allogeneic stem cell transplantation after inotuzumab ozogamicin treatment for relapsed or refractory acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2019.

Ringdén O, Boumendil A, Labopin M, Canaani J, Beelen D, Ehninger G, Niederwieser D, Finke J, Stelljes M, Gerbitz A, et al. OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS OVER 69 YEARS OF AGE WITH ACUTE MYELOID LEUKEMIA: ON BEHALF OF THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT. Biol Blood Marrow Transplant. 2019.

Angenendt L, Hilgefort I, Mikesch J-H, Schlüter B, Berdel WE, Lenz G, Stelljes M, Schliemann C. Magnesium levels and outcome after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. Ann Hematol. 2020.

Derigs P, Bethge WA, Krämer I, Holtick U, von Tresckow B, Ayuk F, Penack O, Vucinic V, von Bonin M, Baldus C, et al. Long-Term Survivors After Failure of CAR-T Cell Therapy for Large B-Cell Lymphoma: A Role for Allogeneic Hematopoietic Cell Transplantation? A GLA/DRST Analysis. Transplant Cell Ther. 2023.

Kantarjian HM, DeAngelo DJ, Stelljes M, Liedtke M, Stock W, Gökbuget N, O'Brien SM, Jabbour E, Wang T, White JLiang, et al. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. Cancer. 2019.

Stelljes M, Raffel S, Alakel N, Wäsch R, Kondakci M, Scholl S, Rank A, Hänel M, Spriewald B, Hanoun M, et al. Inotuzumab Ozogamicin as Induction Therapy for Patients Older Than 55 Years With Philadelphia Chromosome-Negative B-Precursor ALL. J Clin Oncol. 2023:JCO2300546.

Dalle IAbou, Labopin M, Kröger N, Schroeder T, Finke J, Stelljes M, Neubauer A, Blaise D, Yakoub-Agha I, Salmenniemi U, et al. Impact of disease burden on clinical outcomes of AML patients receiving allogeneic hematopoietic cell transplantation: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2023.

Bethge WAndreas, Martus P, Schmitt M, Holtick U, Subklewe M, von Tresckow B, Ayuk F, Wagner-Drouet EMaria, Wulf GG, Marks R, et al. GLA/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany. Blood. 2022.

Gökbuget N, Ihrig K, Stadler M, Stelljes M, Elmaagli A, Starck M, Raffel S, Stoltefuss A, Viardot A, Kreuzer K-A, et al. General condition and comorbidity of long-term survivors of adult acute lymphoblastic leukemia. Haematologica. 2023.

Pages